[Initial experience with aflibercept in the management of patients with wet age-related macular degeneration refractory to ranibizumab and/or bevacizumab].

Age-related macular degeneration (ARMD) is the main cause of vision loss in elderly inhabitants of industrialized countries. The most severe visual loss occurs in the wet or exudative form of ARMD. VEGF-inhibiting drugs administered through intravitreal injection, both ranibizumab (Lucentis® Genentech, South San Francisco, CA, USA), which was approved for this use, and bevacizumab (Avastin®, Genentech, South San Francisco, CA, USA) for compassionate medication, have significantly changed the evolution and visual prognosis of ARMD patients. In any case it is necessary to find new therapies that provide efficacy rates at least equivalent to the monthly administration of ranibizumab, to reduce both the number of visits and injections. Aflibercept, a new therapy also known as VEGF-trap, is capable of inhibiting several growth factors. Pivot studies VIEW 1 and 21 demonstrated that 2-monthly administration of aflibercept was not inferior to the monthly administration of ranibizumab. The authors present their initial experience with intravitreal aflibercept (Eylea®). The objective of the study was to assess the anatomic and visual effect of a single intravitreal aflibercept injection in exudative ARMD patients. The authors carried out a retrospective study at the Ophthalmology Service of the General Hospital of Valencia which includes 10 eyes of 10 different patients with a mean age of 79 ± 8 years, with a diagnosis of active exudative ARMD